Bio-Rad: Uncertainties And Conservatism Continue To Hold Stock Back From Its Full Potential

2025-01-28 21:24:42 ET

Summary

• Bio-Rad has been challenged by tough end-market conditions in life sciences tools, but the outlook for 2025 is better.
• The company's cautious approach has led to lackluster sales growth and margin leverage over the long term, and there are only a handful of meaningful revenue drivers with above-average potential.
• I believe BIO management has long been too conservative and unfocused with its R&D spending, but recent commentary suggests that growth potential and ROI will play a bigger role going forward.
• Bio-Rad's stake in Sartorius remains a significant store of value, but management's long-term plans remain unclear.
• While undervalued and having potential for longer-term growth upside, I remain cautious due to management and strategic concerns, as well as a large reliance on Sartorius to drive overall value.

The past year has been a challenging one for companies in the life sciences tools space, as companies have had to deal with smaller budgets and weaker spending trends among academic and government customers, as well as significantly lower spending levels among biopharma clients after years of above-average spending fueled by the pandemic....

Read the full article on Seeking Alpha

For further details see: